Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 14/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31499204 | 0.93 | ADCY1 (0.55) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL18601237 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL21779505 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL9870844 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL12028527 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL13639992 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL11117898 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL6469176 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL10020759 | 0.87 | ADCY1 (0.60) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL9869567 | 0.84 | ADCY1 (0.45) | ADCY1MAPK1CYP3A4TSHRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0116713-A1 | Novel labdane derivatives, process for the preparation thereof, and pharmaceutical compositions containing labdane derivatives | SCHERING CORPORATION (US) | 1984-08-29 | — | — | EP | claimed |
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2014-05-08 | — | — | US | disclosed |
| US-5247097-A | Intraocular hypotensive | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-09-21 | — | — | US | disclosed |
| US-5130332-A | For reducing intraocular pressure, topical application | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0257631-B1 | OXOLABDANES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-11-06 | — | — | EP | disclosed |
| US-4933476-A | Process for the preparation of novel oxolabdanes | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-06-12 | — | — | US | disclosed |
| US-4883885-A | OXIDATION WITH SELENIUM DIOXIDE, REDUCTION OF INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4782082-A | BRONCHODILATORS, ANTIHISTAMINES | SCHERING CORPORATION (US) | 1988-11-01 | — | — | US | disclosed |
| US-4740522-A | Oxolabdanes useful as pharmaceuticals for reducing intraocular pressure | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-04-26 | — | — | US | disclosed |
| EP-0257631-A2 | Oxolabdanes, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4517200-A | Method for treating allergic reactions with forskolin | SCHERING-PLOUGH CORPORATION (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0116713-A1 | Novel labdane derivatives, process for the preparation thereof, and pharmaceutical compositions containing labdane derivatives | SCHERING CORPORATION (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128399-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | ADCY1 37/4885MAPK1 2510/4885CYP3A4 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.